TIAA Trust, National Association
REGN icon

TIAA Trust, National Association’s Regeneron Pharmaceuticals REGN Stock Holding History

TIAA Trust, National Association’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,426
Closed -$1.1M – 597
2025
Q4 		$1.1M Sell
1,426
-372
-21% -$253K ﹤0.01% 372
2025
Q3 		$1.01M Sell
1,798
-5
-0.3% -$2.83K ﹤0.01% 382
2025
Q2 		$946K Sell
1,803
-24,215
-93% -$13.5M ﹤0.01% 387
2025
Q1 		$16.5M Buy
26,018
+23,997
+1,187% +$16.5M 0.05% 146
2024
Q4 		$1.44M Sell
2,021
-195
-9% -$164K ﹤0.01% 326
2024
Q3 		$2.33M Sell
2,216
-18
-0.8% -$20K 0.01% 286
2024
Q2 		$2.35M Sell
2,234
-33
-1% -$32K 0.01% 261
2024
Q1 		$2.18M Sell
2,267
-79
-3% -$75.1K 0.01% 276
2023
Q4 		$2.06M Buy
2,346
+180
+8% +$148K 0.01% 268
2023
Q3 		$1.78M Buy
+2,166
New +$1.7M 0.01% 267

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

TIAA Trust, National Association's REGN Position: Q1 2026 in Review

TIAA Trust, National Association sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 1,426 shares — an estimated $1.1M sold.

TIAA Trust, National Association first reported a position in REGN in Q3 2023 and held it in 10 quarters. The position peaked at $16.5M in Q1 2025. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • TIAA Trust, National Association reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • TIAA Trust, National Association sold 1,426 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.1M.
  • TIAA Trust, National Association first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 10 quarters.
  • TIAA Trust, National Association's Regeneron Pharmaceuticals position peaked at $16.5M in Q1 2025.
  • 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on TIAA Trust, National Association's 13F filing for Q1 2026, filed 12 May 2026.